Drug Approval | January 24, 2025
Shilpa Pharma Lifesciences received CEP from EDQM for API, Teriflunomide
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
This is used to treat central diabetes insipidus and bedwetting
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
The Unit has been issued GMP Certification from ANVISA-Brazil
The inspection has concluded successfully on 1st September 2023 without any critical/major observation
Subscribe To Our Newsletter & Stay Updated
